top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hGLP1R mice
Strain Name C57BL/6-Glp1rtm1(GLP1R)/Bcgen Common Name  B-hGLP1R mice
Background C57BL/6 Catalog number  170164
Related Genes 
GLP-1; GLP-1R; GLP-1-R
NCBI Gene ID
14652

mRNA and protein expression analysis

from clipboard


The mRNA of human GLP1R was detectable in the lung of the homozygous B-hGLP1R mice,but not detectable in wildtype mice. While the mouse GLP1R mRNA was not detectable in homozygous B-hGLP1R mice. Also we proved that the protein could be expressed normally by western blot analysis. Human and mouse cross-reactive antibodies were used to detect the GLP1R of the wildtype and humanized GLP1R mice.


Protein expression analysis


from clipboard
IHC for human GLP1R expression. Pancreata from wild-type (+/+) and B-hGLP1R mice (H/H) were stained using an antibody specific for human GLP1R. and only the pancreas from B-hGLP1R mice (H/H) showed hGLP1R positive signal in plasma membrane.

Analysis of leukocytes cell subpopulation in B-hGLP1R mice


from clipboard

from clipboard

Analysis of leukocyte subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hGLP1R mice (n=3, 9-week-old). Flow cytometry analysis of the splenocytes were performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, monocytes, dendritic cells, granulocytes and macrophages in homozygous B-hGLP1R mice were similar to those in the C57BL/6 mice, demonstrating that GLP1R humanized does not change the overall development, differentiation or distribution of these cell types in spleen. The same results were observed in blood and lymph node, data was not shown. Values are expressed as mean ± SEM.


Analysis of leukocytes cell subpopulation in B-hGLP1R mice



from clipboard


Analysis of T cell subpopulation in spleen by FACS. The lymphocytes were isolated from spleen in C57BL/6 and B-hGLP1R mice (n=3, 9-week-old). The proportion of T cells subpopulation was tested by flow cytometry. There were no differences between C57BL/6 and B-hGLP1R mice, demonstrating that humanized of GLP1R does not change the overall development, differentiation or distribution of these T cell subtypes. The same results were observed in blood and lymph node, data was not shown. Values are expressed as mean ± SEM.


Dulaglutide reduces blood glucose in B-hGLP1R mice

from clipboard

Dulaglutide reduces blood glucose in B-hGLP1R mice. Blood was collected from C57BL/6 mice and B-hGLP1R mice (male, 7-8w, n=5) at multiple time points after injection of Dulaglutide (in house) or PBS for analysis. (A). Body weight. (B). Non-fasting blood glucose. (C). Fasting blood glucose. (D). IPGTT. (E). Area under the curve for the IPGTT. The body weight has no significant change during the experiment. Dulaglutide reduced the non-fasting blood glucose and fasting blood glucose compared to the PBS in C57BL/6 and B-hGLP1R mice. For the IPGTT results, B-hGLP1R mice and wild-type mice display similar physiological responses for glucose metabolism. Values are expressed as mean ± SEM. IPGTT, Intraperitoneal glucose tolerance test.


Dulaglutide reduces food instake in B-hGLP1R mice


from clipboard

Dulaglutide decreased food intake in B-hGLP1R mice. Food intake was monitored in C57BL/6 and B-hGLP1R mice (male, 15w, n=5) after treatment with dulaglutide for 24 and 48 hours separately, then calculated for each cage and corrected for food intake per mouse. (A). Food intake in 24h. (B). Food intake in 48h. Dulaglutide decreased food intake both in C57BL/6 and B-hGLP1R mice. Values are expressed as mean ± SEM.


Model schematic and antibody evaluation scheme


from clipboard


Schedule for in vivo efficacy of Dulaglutide. B-hGLP1R (male, n=10) mice were fed with high-fat diet for 12 weeks to induce mice obesity. Then, the mice were randomized according to body weight. About 24 hours before or after injected drugs,  measured and calculated the food intake. The Dulaglutide (in house) was subcutaneous injection every two days from Day 1 to 8 after grouping. Blood was collected to measure blood glucose and IPGTT on the days shown in the schematic diagram and the table. Measure plasma insulin during the IPGTT.


Dulaglutide reduces blood glucose in B-hGLP1R mice with obesity

from clipboard

Dulaglutide reduces blood glucose in B-hGLP1R mice with obesity. Blood was collected from B-hGLP1R mice (male, n=10) at multiple time points after injection of Dulaglutide (in house) or PBS for analysis. (A). Body weight. (B). Non-fasting blood glucose. (C). Fasting blood glucose. (D). Serum glucose levels following intraperitoneal glucose challenge. (E). Area under the curve (AUC) for the IPGTT. (F). Food intake. Dulaglutide resulted in no weight loss during the experiment, and reduced the non-fasting blood glucose and fasting blood glucose compared to PBS. For the IPGTT results, glucose tolerance was improved by dulaglutide compared to PBS. The results show that B-hGLP1R mice provide an efficacious preclinical animal model for evaluating related drugs. Values are expressed as mean ± SEM. IPGTT, Intraperitoneal glucose tolerance test.


Dulaglutide decreased food intake/glucagon and increased insulin/GLP-1 secretion in B-hGLP1R mice with obesity

from clipboard

Dulaglutide regulated blood glucose by increasing insulin and decreased glucagon secretion in B-hGLP1R obesity mice, and influenced the food intake. Food intake was measured in C57BL/6 and B-hGLP1R mice (male, n=10) after treatment with dulaglutide for 24h, then calculated for each cage and corrected for food intake per mice. The plasma insulin was measured during the IPGTT. And collected the serum for GLP-1 and glucagon analysis. (A) Food intake in 24h after treatment. (B). Plasma insulin secretion. (C). The area under the curve for plasma insulin during 0-30 minutes. (D). Serum GLP-1. (E). Serum Glucagon. Dulaglutide decreased food intake in B-hGLP1R mice. Meanwhile, Insulin and GLP-1 increased, glucagon secretion decreased after treatment with Dulaglutide, which is consistent with the mechanisms of control blood glucose. Values expressed as mean ± SEM. IPGTT, Intraperitoneal glucose tolerance test.


PF-06882961 improved glucose tolerance in B-hGLP1R mice with obesity

from clipboard

PF-06882961 improved glucose tolerance in B-hGLP1R mice with obesity. (A). Serum glucose levels following intraperitoneal glucose challenge (IPGTT). (B). Area under the curve (AUC) for the IPGTT. Glucose tolerance was improved by PF-06882961 compared to vehicle in B-hGLP1R mice but not in wild-type C57BL/6 mice. The results show that B-hGLP1R mice provide an efficacious preclinical animal model for evaluating species-specific new 'biological' medicines. Values are expressed as mean ± SEM. (PF-08882961 is a small molecule agonist for human GLP1R).